Shire and TAP Pharmaceutical Products Inc. have inked a three-year, U.S. co-promotion pact for Shire’s Lialda with MMX technology, which is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). The agreement will add more than 500 sales representatives from TAP to increase the reach and frequency of the Shire sales force, which consists of 120 representatives who are currently detailing Lialda primarily to gastroenterologists. &#8220...